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Abstract 
MOSkin detectors were studied to perform real-time in vivo dose measurements in high dose rate 
prostate brachytherapy. Measurements were performed inside an urethral catheter in a gel phantom 
simulating a real prostate implant. Measured and expected doses were compared and the discrepancy 
was found to be within 8.9% and 3.8% for single MOSkin and dual-MOSkin configurations, respectively. 
Results show that dual-MOSkin detectors can be profitably adopted in prostate brachytherapy treatments 
to perform real-time in vivo dosimetry inside the urethra. 
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• A needles implant was set up in phantom to simulate prostate brachytherapy treatments 
• In vivo dosimetry was performed in the urethral catheter with MOSkin dosimeters 





MOSkin detectors were studied to perform real-time in vivo dose measurements in high dose rate 
prostate brachytherapy. Measurements were performed inside an urethral catheter in a gel phantom 
simulating a real prostate implant. Measured and expected doses were compared and the 
discrepancy was found to be within 8.9% and 3.8% for single MOSkin and dual-MOSkin 
configurations, respectively. Results show that dual-MOSkin detectors can be profitably adopted  in 










1.1 In vivo dosimetry in radiotherapy 
The recent developments of more sophisticated radiotherapy and brachytherapy (BT) techniques 
call for the improvement of instruments and methodologies employed for the quality control of the 
performed treatments. Due to the achievable high conformity of modern BT associated with  steep 
dose gradients, a careful verification of the accuracy in the delivered dose distributions, as planned 
by the Treatment Planning System (TPS) through mathematical models, is gaining importance. 
In vivo dosimetry is a reliable method to compare planned and delivered dose distributions, 
representing therefore a valid tool to systematically verify treatment accuracy and improve 
radiotherapy quality control (Lambert et al 2007, Mijnheer 2008). Particularly advantageous for in 
vivo dosimetry are detectors that allow on-line dose reading. These dosimeters provide in fact real-
time measurements during treatment, avoiding therapy misadministration and allowing at the same 
time intraoperative dose re-planning for treatment error correction.  
Current methods for in vivo dosimetry are mainly based on the application of thermoluminescence 
detectors (TLDs) (Toye et al 2009) or semiconductor diodes (Waldhäusl et al 2005). TLDs involve 
offline process providing the integral dose absorbed during patient treatment and require special 
procedures in order to achieve good precision of the results. On the other hand, diodes show rapid 
processing time, high sensitivity and immediate reuse, however, they show a high energy 
dependence and the delivered dose is therefore not promptly inferred from the diode reading. 
Moreover, the major disadvantages of diodes are their relative large sizes, which make them unable 
to be held in many catheters placed inside the patient to perform in vivo dosimetry. 
New detectors such as fiber optic coupled scintillation dosimeters (Suchowerska et al 2007, 
Therriault-Proulx et al 2011) and metal oxide semiconductor field effect transistors (MOSFETs) 
(Zilio et al 2006, Fagerstrom et al 2008) have recently been introduced to perform in vivo 




sensitivity, real time read-out without deterioration of information, negligible radiation field 
perturbation owing to their small size and ease of use. In particular, great interest was dedicated to 
the application of MOSFETs to BT, because the typical large dose gradients achieved in BT 
necessitate a small detector with a reduced active volume for accurate dosimetry. In this work, a 
specific type of MOSFET dosimeter called “MOSkin” which has developed by the Centre for 
Medical Radiation Physics (CMRP) of the University of Wollongong (Australia) (Qi et al 2007, 
Kwan et al 2008, Kwan et al 2009) has been  studied. 
1.2 High dose rate prostate brachytherapy 
High dose rate (HDR) prostate BT allows the delivery of local and high conformal dose directly 
into the tumour, minimizing exposure of the surrounding healthy tissues. Due to the large dose 
delivered to the target in a single fraction and the dose constraints to be simultaneously satisfied for 
organs at risk , it is very important to have as  small as  possible discrepancy between planned and 
delivered dose. The development and application of reliable and accurate methods for monitoring 
the dose delivered to critical organs is therefore crucial. 
Among these organs at risk, the urethra is most likely susceptible to acute and/or late toxicity 
resulting from the treatment (i.e. urethritis, stenosis), as it is inside the target volume (figure 1a). 
However, its localization for treatment planning purposes is particularly difficult due to images 
artefacts generated by the presence of source catheters, especially if transrectal ultrasound imaging 
is performed. Moreover, source catheters are themselves difficult to be accurately localized on the 
same images and therefore calculated dose distributions are susceptible to inaccuracies (figure 1b). 
The real time dosimetry in the urethra is therefore very important and  will  be  supplementary to 
reinforce existing QA programs. 
Studies aimed at characterizing the dosimetric properties of MOSkin dosimeters have already 
demonstrated that they are promising instruments for performing in vivo dosimetry during HDR BT 




accuracy of the dosimeters and the change in sensitivity as a function of depth and angle of 
incidence of the radiation, have already shown good agreement between MOSkin response and dose 
calculated by the TPS (Hardcastle et al 2010). Aim of this work was to study and develop the 
applicability of the MOSkin dosimeters for urethral dose measurement in prostate HDR BT.  
 
2. Materials and Method 
 
2.1 MOSkin dosimetry system   
The design of this particular type of MOSFET is optimized to measure dose in steep dose gradients. 
Different from other commercial MOSFETs, MOSkin die is embedded in  a thin kapton layer and 
hermetically sealed with water-equivalent flexible carrier of reproducible thickness and avoid traditional 





. MOSkin detectors can be adopted alone or coupled in a face-to-face arrangement. This face-to-face 
dual-MOSkin arrangement is referred to in this text as the “dual-MOSkin”. The dual-MOSkin, proposed and 
developed at CMRP, allows for angular-independent measurements as it compensates the naturally 
asymmetrical structure of the MOSFET chip relative to the beam direction
 
(Hardcastle et al 2010). The 
dosimetry system adopted with MOSkin detectors includes a microprocessor based reader which is connected 
to a laptop provided with a dedicated software (“MosPlot”). The computer data acquisition system measures 
periodically the instantaneous voltage signal with a user defined frequency. The “MosPlot” software allows 
for the online graphical representation of the change in the threshold voltage (proportional to accumulated 
dose) or increments in the threshold voltage for consecutive readouts (proportional to dose rate).  
 
2.2 Nucletron Microselectron-HDR Brachytherapy facility 
BT irradiations were performed using a Microselectron-HDR (Nucletron,Veenendaal, the 






radioactive source which has an active length of 3.6mm and a diameter of 0.65mm. The source is 
sealed inside a capsule that is welded to one end of a flexible steel cable and the treatment unit 
moves it to the required dwell positions. 
Experimental determinations of absolute dose rates to water from high-energy sources should have 
direct traceability of the source Air Kerma Strength Sk to a primary or secondary standard 
dosimetry laboratory (PSDL OR SSDL) (Perez-Calatayud et al, 2012). In our case, the Sk was 
certificated by the vendor with 5% (k=3) uncertainty using a calibration instrument traceable to the 
standard of the PSDL Physikalisch-Technische Bundesanstalt (PTB, Braunschweig, Germany). 
Moreover, the certified Sk was independently verified at our hospital before its clinical application, 
by the qualified medical physicist using a calibrated well-type chamber traceable to a PSDL. The 
well-type chamber has a vented sensitive volume of 200cc (Source Dosimetry System. Nucletron, 
Veenendaal, the Netherlands) (Nath et al 1997) and has proven to be a fast and precise measuring 
instrument (Azhari et al, 2012). The delivered dose distribution is calculated by TPS Oncentra 
Brachytherapy (Nucletron, Veenendaal, the Netherlands) and is based on the recommendations of 
the American Association of Physics in Medicine (AAPM) TG-43 report (Rivard et al 2004).. 
 
2.3 MOSkin and dual-MOSkin calibration and response at increasing source-detector distance   
Each single MOSkin and dual-MOSkin was calibrated in a water phantom at a distance of 38mm 
from the 
192
Ir HDR source. A suitable support for accurate and reproducible detector and source 
positioning was developed to perform this task (figure 2) and the experimental set-up was 
accurately defined by means of CT imaging (slice thickness: 0.8mm) and catheter digital 
reconstruction. Five irradiations were performed for defined source dwell times and the mean 
values of MOSkin threshold voltage changes were obtained. Each detector was finally calibrated 
considering the correspondent dose value calculated by means of the TPS in the same position 
where the active component of the dosimeter was placed. To investigate  MOSkin sensitivity 




192 source, distance dependent correction factor (CF) was evaluated for measurements performed 
at locations other than the calibration position, ranging from 7mm to 46mm and from 11mm to 
44mm along the source transverse axis in the water phantom for MOSkin and dual-MOSkin 
dosimeters, respectively. In each one of these locations, measurements were repeated five times.   
 
2.4  In phantom simulations of prostate treatments  
With the aim of performing dose measurements with implants and conditions simulating typical 
prostate treatments, a suitable gel phantom was realized. The phantom has a cylindrical shape with 
length  of 14.5 cm, and a diameter of 17.6 cm. The urethral catheter and 14 interstitial needles were 
placed inside the gel phantom through a real prostate treatment template. Single or dual-MOSkins 
were inserted in the urethral catheter. CT images (0.8mm slice thickness) were acquired in order to 
precisely localize needles and the urethral catheter containing the dosimeter. In the treatment 
planning phase, the presence of a prostate was virtually created by drawing it on the CT images 
around the needles implant. The urethral catheter was as well segmented and different treatments 
were planned by prescribing the dose to the outlined  prostate. The expected doses to the dosimeters 
were evaluated from the TPS. In fact, MOSkin detectors could be accurately recognized on CT 
images’ reconstructions as small radiopaque spots inside the urethral catheter (figure 3). During 
irradiation, the plastic needles were connected to the BT afterloader system thought transfer tubes 
and MOSkins were connected to the CMRP computerized reader for the on-line acquisition of dose 
measurements (figure 4). 
A series of measurements of the same irradiation set-up was performed with different dose 
prescriptions according to the developed treatment plans. The total urethral dose measured with the 
single or dual-MOSkin detector was compared to the expected dose in the same point. Moreover, 
the contributions to the total dose given by the source moving in each single needle were calculated 





3. Results and discussion 
Single MOSkin and dual-MOSkin detectors calibration factors obtained in the water phantom on the 
Ir-192 source resulted 0.38 cGy/mV and 0.30 cGy/mV, respectively. Distance dependent CFs at 
different source-detector distances for single MOSkin data were in accordance with those reported 
in Qi et al (2012); the significant increase of CF at decreasing source-detector distance was 
observed. In contrary to single MOSkins, CFs for dual-MOSkins showed a relatively flat response 
with changing the Ir-192 source-detector distance (figure 5). It is important to note that reference 
dose data to perform dosimeter calibration were not obtained experimentally by a further dosimeter, 
but were those resulting from the TPS and cross-checked with a home made software based on the 
AAPM TG-43 algorithm (Rivard et al, 2004). The chosen Λ, G(r,θ), F(r,θ) and g(r) factors were 
those tabulated in Daskalov et al (1998), which were obtained by means of a Monte Carlo (MC) 
photon transport code knowing the characteristics of the Nucletron model mHDR-v2 source. 
Consensus on these data has been widely achieved and the resulting AAPM TG-43 algorithm 
calculations, when performed in reference conditions of unbounded water medium, are highly 
accurate (Daskalov et al, 1998). In fact, the role of experimental dosimetry for high-energy BT may 
be more limited than MC-based dosimetry. With high energy BT sources, range and spatial 
resolution limitations are for instance not of concern for MC methods (Perez-Calatayud et al, 2012). 
Comparison of total dose measured in the gel phantom for the BT prostate implant with the single-
MOSkin detector and the expected doses in the same points are reported in Table 1. Measurements 
were repeated for three different treatment plans with different dose prescriptions. The maximum 
discrepancy between expected and measured dose was found to be 8.9%. Figure 6a shows measured 
and calculated contribution to the total dose resulting by the source dwelling  in each of the 14 




Excluding needles that give a low contribution to the cumulative dose (<20cGy), single point dose 
differences resulted less than 15%. 
Comparison of total doses measured with the dual-MOSkin detector and the expected doses in the 
same point is reported in Table 2 for three different measurement sessions. It was found that 
discrepancy was within 3.8%. Figure 6b shows measured and calculated contribution to the total 
dose resulting by the source moving in each of the 14 needles adopted to simulate the prostate 
implant, for one of the measured treatment sessions. Excluding needles that give a low contribution 
to the cumulative dose (<20cGy), single dose differences resulted in general smaller then those 
resulting with a single MOSkin readings (i.e. max 8%). 
Results obtained for both single MOSkin and dual-MOSkin dosimeters are summarized in the plot 
in figure 7. Dual-MOSkin configuration provides greater accuracy than a single MOSkin detector as 
angular isotropy and depth dose are greatly improved. Single MOSkin accuracy could be partially 
increased by applying measured CFs at changing source-detector distances and further CFs that take 
into account its orientation with respect to the source position. However, CFs are almost impossible 
to be correctly adopted whenever MOSkins are used as real-time in vivo dosimeters because source-
detector distances and MOSkin orientation cannot be easily quantified and taken into account. 
 
4. Conclusions 
In prostate HDR BT treatments, a very high dose over a few fractions is delivered. In such 
conditions, real time dosimetry is most valuable in detecting a dose error at the onset of treatment, 
providing the capability of immediate corrections. Measurements performed in a phantom 
simulating a typical prostate implant with MOSkin detectors placed within the urethral catheter have 
shown that they allow evaluation of the actual dose to the urethra during a treatment fraction. 




might offer a further security to detect and prevent significant errors in the clinical routine of HDR 
BT prostate treatments.  
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Figure 1: a) 3D graphical representation of an HDR brachytherapy plan of the prostate (dark red). 
Urethra, rectum and bladder are represented in yellow, green and blue, respectively. Source 
catheters are drawn as green lines, source dwell positions are represented by red spheres and 
resulting dose distribution (95% isodose) is given in light blue; b) transversal prostate image with 
the resulting dose distribution. Characteristic hot spots are present around some of the implanted 
needles. 
 
Figure 2: Support to be placed in a water phantom which was developed for dosimeters calibration. 
Source catheter can be placed at different distances from the dosimeter. 
 
Figure 3: a) sagittal CT reconstruction and b) transversal CT image including the urethral catheter. 
MOSkin dosimeter is clearly recognizable as a radiopaque spot inside the catheter. 
 
Figure 4: Experimental set-up used for in phantom measurements. 
 
Figure 5: Correction factors evaluated at different source-detector distances for single- (white 
circles) and dual-MOSkin (gray diamonds) detectors. Plotted error bars are given by the standard 
deviation of the measurements and result in the values of 0.025, 0.018, 0.018, 0.019, 0.020, 0.019 
and of 0.046, 0.042, 0.043, 0.048, 0.034, 0.032 for single- and dual-MOSkin, respectively. 
 
Figure 6: Measured and expected doses given by the source moving in each of the 14 needles for a) 
MOSkin and b) dual-MOSkin detectors.  
 
Figure 7: Comparison between single MOSkin and dual-MOSkin in terms of measured mean dose 





Table 1: Total urethral dose measured with a single-MOSkin dosimeter for three different treatments. 
Total urethral dose 






1 727.2 798.1 -8.9 
2 809.2 828.1 -2.0 
3 732.0 799.0 -8.0 
 
 
Table 2: Total urethral dose measured with a dual-MOSkin dosimeter for three sessions of the same 
treatment. 
Total urethral dose 






1 1139.5 1148.5 -0.8 
2 1126.7 1148.5 -1.9 
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